Skip to search formSkip to main contentSkip to account menu

EPOCH protocol

Known as: EPOCH, CTX/DOX/PRED/VCR/VP-16, Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin Regimen 
A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (3)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideEtoposide
DoxorubicinDoxorubicin HydrochlorideLymphoma, Non-HodgkinMalignant lymphoma, lymphocytic, intermediate differentiation, diffuse

Narrower (1)

VACPE protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Outcomes of treatment with dose‐adjusted EPOCH‐R or R‐CHOP in primary mediastinal large B‐cell lymphoma
The standard first‐line treatment for primary mediastinal B‐cell lymphoma (PMBCL) patients is rituximab‐based immunochemotherapy… 
Highly Cited
2015
Highly Cited
2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B‐cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort
Gray zone lymphoma (GZL) with features between classical Hodgkin lymphoma and diffuse large B‐cell lymphoma (DLBCL) is a recently… 
Highly Cited
2015
Highly Cited
2015
Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group
This prospective multi‐institutional phase II study was designed to assess the efficacy and safety of dose‐adjusted EPOCH… 
Highly Cited
2014
Highly Cited
2014
A prospective study of mediastinal gray-zone lymphoma.
Mediastinal B-cell lymphomas present in the mediastinum and are most frequent in young patients. Nodular sclerosis Hodgkin… 
Highly Cited
2013
Highly Cited
2013
Low-intensity therapy in adults with Burkitt's lymphoma.
BACKGROUND Burkitt's lymphoma is an aggressive B-cell lymphoma that occurs in children and adults and is largely curable with the… 
Highly Cited
2012
Highly Cited
2012
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
Background A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA… 
2007
2007
Dose‐adjusted EPOCH plus rituximab is an effective regimen in patients with poor‐prognostic untreated diffuse large B‐cell lymphoma: results from a prospective observational study
This study was designed to assess the efficacy and safety of an infusional DA‐EPOCH (dose‐adjusted etoposide/vincristine… 
2006
2006
Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a…
PMBL is a distinct clinicopathologic entity characterized by young age, female preponderance, localized disease, prominent… 
Review
2004
Review
2004
Non-Hodgkin's Lymphoma in Job's Syndrome: A Case Report and Literature Review
Job's or hyper immunoglobulin E recurrent infection syndrome (Hyper-IgE syndrome) is a rare, often inherited multisystem disorder… 
2004
2004
[Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
BACKGROUND & OBJECTIVES The biological behavior of peripheral T-cell lymphoma (PTCL) are different from that of B-cell non… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)